Biomark Diagnostics Statistics
Total Valuation
Biomark Diagnostics has a market cap or net worth of 10.30 million. The enterprise value is 11.30 million.
| Market Cap | 10.30M |
| Enterprise Value | 11.30M |
Important Dates
The next estimated earnings date is Wednesday, February 26, 2025.
| Earnings Date | Feb 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.88% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 39.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.76 |
| EV / Sales | 103.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -12.96 |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.26 |
| Interest Coverage | -26.81 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -168.69% |
| Return on Capital (ROIC) | -325.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.72% in the last 52 weeks. The beta is -0.54, so Biomark Diagnostics's price volatility has been lower than the market average.
| Beta (5Y) | -0.54 |
| 52-Week Price Change | -25.72% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 13.59 |
| Average Volume (20 Days) | 1,094 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biomark Diagnostics had revenue of 116,961 and -1.46 million in losses. Loss per share was -0.02.
| Revenue | 116,961 |
| Gross Profit | 116,961 |
| Operating Income | -1.51M |
| Pretax Income | -1.46M |
| Net Income | -1.46M |
| EBITDA | -1.50M |
| EBIT | -1.51M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 25,645 in cash and 1.10 million in debt, giving a net cash position of -1.08 million.
| Cash & Cash Equivalents | 25,645 |
| Total Debt | 1.10M |
| Net Cash | -1.08M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -765,667 |
| Book Value Per Share | -0.01 |
| Working Capital | -1.00M |
Cash Flow
In the last 12 months, operating cash flow was -867,706 and capital expenditures -4,401, giving a free cash flow of -872,107.
| Operating Cash Flow | -867,706 |
| Capital Expenditures | -4,401 |
| Free Cash Flow | -872,107 |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,289.70% |
| Pretax Margin | -1,245.91% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biomark Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.88% |
| Shareholder Yield | -0.88% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biomark Diagnostics has an Altman Z-Score of -26.83. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -26.83 |
| Piotroski F-Score | n/a |